JP2016026491A - Solid composition - Google Patents
Solid composition Download PDFInfo
- Publication number
- JP2016026491A JP2016026491A JP2015128641A JP2015128641A JP2016026491A JP 2016026491 A JP2016026491 A JP 2016026491A JP 2015128641 A JP2015128641 A JP 2015128641A JP 2015128641 A JP2015128641 A JP 2015128641A JP 2016026491 A JP2016026491 A JP 2016026491A
- Authority
- JP
- Japan
- Prior art keywords
- component
- solid composition
- fat globule
- mass
- globule membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明は、脂肪球皮膜成分を含有する固形状組成物に関する。 The present invention relates to a solid composition containing a fat globule membrane component.
脂肪球皮膜成分(Milk−fat Globule Membrane)は、乳腺より分泌される乳脂肪球を被覆している膜成分で、バターミルクやバターセーラム等の乳複合脂質高含有画分に多く含まれることが知られている(非特許文献1)。脂肪球皮膜成分は、脂肪を乳汁中に分散させる機能を有するのみならず、筋力等の運動機能向上作用、内臓脂肪蓄積抑制作用、血中アディポネクチン増加及び減少抑制作用等の多くの生理機能を有することが報告されている(特許文献1及び2)。
近年、メタボリックシンドロームやロコモティブシンドロームの患者数が著しく増加し、社会的に大きな問題となっていることから、前述したような生理機能を有する脂肪球皮膜成分の幅広い利用が期待されている。
The fat globule membrane component (Milk-fat Globule Membrane) is a membrane component that coats milk fat globule secreted from the mammary gland, and is often contained in high fractions of milk complex lipids such as buttermilk and buttersarum. It is known (Non-Patent Document 1). The fat globule membrane component not only has the function of dispersing fat in milk, but also has many physiological functions such as an improvement in motor function such as muscle strength, an action to suppress visceral fat accumulation, an action to suppress increase and decrease in blood adiponectin, etc. (Patent Documents 1 and 2).
In recent years, the number of patients with metabolic syndrome and locomotive syndrome has increased remarkably and has become a major social problem, and therefore, widespread use of fat globule membrane components having physiological functions as described above is expected.
脂肪球皮膜成分の生理機能を効果的に得るには、手軽に無理なく長期間継続して摂取可能な錠剤のような固形状組成物形態とするのが望ましいが、現在販売されている脂肪球皮膜成分を含有する錠剤は、脂肪球皮膜成分を極めて低濃度で含有するものである。脂肪球皮膜成分の生理機能を得るためには、脂肪球皮膜成分(乾燥物換算)として、成人に対して1日あたり、10mg/60kg体重以上とするのが好ましいと考えられている(特許文献1)。そのため、脂肪球皮膜成分を高濃度で配合して1回当たりの固形状組成物の摂取量を少量に設定することが求められる。 In order to effectively obtain the physiological function of the fat globule membrane component, it is desirable to use a solid composition form such as a tablet that can be easily and easily ingested for a long period of time. A tablet containing a film component contains a fat globule film component in an extremely low concentration. In order to obtain the physiological function of the fat globule membrane component, it is considered that the fat globule membrane component (in terms of dry matter) is preferably 10 mg / 60 kg body weight or more per day for an adult (patent document) 1). Therefore, it is required to mix the fat globule membrane component at a high concentration and set the intake amount of the solid composition per time to a small amount.
しかしながら、本発明者らが検討したところ、一度少量摂取するだけで生理機能を期待できるほどの高い濃度で脂肪球皮膜成分を固形状組成物中に配合することは困難であることが判明した。すなわち、脂肪球皮膜成分を高濃度化すると、意外にも脂肪球皮膜成分特有の乳風味を感じ難い場合があり、摂食時に良好な風味を感じ難いこと、また、柔らかすぎて、摂食中にねとつきが生じ、口内に付着して摂取し難いことが判明した。
したがって、本発明は、高濃度の脂肪球皮膜成分を含みながらも風味が良好で、摂取し易い固形状組成物を提供することに関する。
However, as a result of investigations by the present inventors, it has been found that it is difficult to blend a fat globule membrane component into a solid composition at such a high concentration that a physiological function can be expected only by taking a small amount once. That is, when the concentration of the fat globule membrane component is increased, the milk flavor peculiar to the fat globule membrane component may unexpectedly be difficult to feel, and it may be difficult to feel a good flavor at the time of eating. It turned out to be sticky and sticking in the mouth, making it difficult to ingest.
Therefore, the present invention relates to providing a solid composition that contains a high concentration of fat globule membrane component but has a good flavor and is easy to ingest.
本発明者らは、上記課題を解決するため鋭意検討を重ねた結果、脂肪球皮膜成分に所定の糖類を所定の範囲で組み合わせることにより、脂肪球皮膜成分特有の乳風味が強まり、口内に良好な風味が広がること、また、口内でのねとつき・付着性が改善されて摂取し易い、風味及び食感の良好な固形状組成物とすることができることを見出した。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have combined the predetermined sugars with the fat globule membrane component in a predetermined range, thereby enhancing the milk flavor peculiar to the fat globule membrane component and being good in the mouth It has been found that a solid composition with a good flavor and texture that can be easily ingested with improved mouthfeel and adhesion in the mouth.
すなわち、本発明は、次の成分(A)、(B)及び(C):
(A)脂肪球皮膜成分 20質量%以上、
(B)乳糖 5質量%以上、
(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類
を配合してなり、成分(A)の配合量に対する成分(B)と成分(C)の合計配合量の比(配合質量比)[{(B)+(C)}/(A)]が0.5〜3.5であり、且つ成分(B)と成分(C)の合計配合量に対する成分(B)の配合量の比(配合質量比)[(B)/{(B)+(C)}]が0.08〜0.72である固形状組成物を提供するものである。
That is, the present invention includes the following components (A), (B) and (C):
(A) Fat globule film component 20% by mass or more,
(B) Lactose 5% by mass or more,
(C) At least one saccharide selected from disaccharides other than lactose and monosaccharides is blended, and the ratio of the total blending amount of component (B) and component (C) to the blending amount of component (A) (Blending mass ratio) [{(B) + (C)} / (A)] is 0.5 to 3.5, and component (B) relative to the total blending amount of component (B) and component (C) A solid composition having a ratio (blending mass ratio) [(B) / {(B) + (C)}] of 0.08 to 0.72 is provided.
本発明によれば、脂肪球皮膜成分に乳糖およびその他の糖類を添加することにより固形状組成物を得るため、脂肪球皮膜成分を高濃度に含有しながらも脂肪球皮膜成分に由来する良好な乳風味が感じられて、摂食時の風味に優れ、また、口内でのねとつき・付着が少ない、風味及び食感の良好な固形状組成物を提供することができる。本発明の固形状組成物は、少量摂取するだけで脂肪球皮膜成分の生理効果発現に必要な量を摂取できるので、脂肪球皮膜成分による効果を長期に亘って十分に期待できる。 According to the present invention, in order to obtain a solid composition by adding lactose and other saccharides to the fat globule membrane component, a good content derived from the fat globule membrane component while containing the fat globule membrane component in a high concentration It is possible to provide a solid composition having a good flavor and texture, having a milky taste, excellent taste at the time of eating, and having less stickiness and adhesion in the mouth. Since the solid composition of the present invention can be ingested in an amount necessary for manifesting the physiological effect of the fat globule membrane component only by ingesting a small amount, the effect of the fat globule membrane component can be sufficiently expected over a long period of time.
本発明で用いられる(A)脂肪球皮膜成分は、乳脂肪球を被覆している膜、及び膜を構成する成分の混合物と定義されている。脂肪球皮膜は、一般的に、乾燥重量の約半分が脂質で構成され、当該脂質としては、トリグリセライドやリン脂質、スフィンゴ糖脂質が含まれることが知られている(三浦晋、FOOD STYLE21、2009及びKeenan TW、Applied Science Publishers、1983、pp89−pp130)。リン脂質としては、スフィンゴミエリン等のスフィンゴリン脂質、ホスファチジルコリンやホスファチジルエタノールアミン等のグリセロリン脂質が含まれることが知られている。
また、脂質以外の成分としては、ミルクムチンと呼ばれる糖タンパク質が含まれることが知られている(Mather、Biochim Biophys Acta、1978)。
The (A) fat globule membrane component used in the present invention is defined as a film covering milk fat globules and a mixture of components constituting the membrane. The fat globule membrane is generally composed of lipids in about half of the dry weight, and the lipids are known to include triglycerides, phospholipids, and glycosphingolipids (Miura Akira, FOOD STYLE 21, 2009). And Keenan TW, Applied Science Publishers, 1983, pp89-pp130). It is known that phospholipids include sphingophospholipids such as sphingomyelin and glycerophospholipids such as phosphatidylcholine and phosphatidylethanolamine.
In addition, it is known that a component other than lipid includes a glycoprotein called milk mucin (Mother, Biochim Biophys Acta, 1978).
本発明で用いられる(A)脂肪球皮膜成分は、生理効果の点から、脂質の含有量が、10質量%(以下、単に「%」とする)以上、更に20%以上、更に30%以上であるのが好ましく、また、風味・ハンドリングの点から、100%以下、更に90%以下、更に60%以下であるのが好ましい。また、脂肪球皮膜成分中の脂質の含有量は、10〜100%、更に20〜90%、更に30〜60%が好ましい。 The fat globule membrane component (A) used in the present invention has a lipid content of 10% by mass (hereinafter simply referred to as “%”) or more, further 20% or more, and further 30% or more from the viewpoint of physiological effects. From the viewpoint of flavor and handling, it is preferably 100% or less, more preferably 90% or less, and further preferably 60% or less. Further, the lipid content in the fat globule membrane component is preferably 10 to 100%, more preferably 20 to 90%, and further preferably 30 to 60%.
また、(A)脂肪球皮膜成分は、生理効果の点から、リン脂質の含有量が5%以上、更に8%以上、更に10%以上、更に15%以上であるのが好ましく、また、風味・ハンドリングの点から、100%以下、更に85%以下、更に70%以下、更に60%以下であるのが好ましい。また、脂肪球皮膜成分中のリン脂質の含有量は、5〜100%、更に8〜90%、更に10〜70%、更に15〜60%が好ましい。
また、(A)脂肪球皮膜成分は、生理効果の点から、リン脂質としてスフィンゴミエリンを含むのが好ましく、脂肪球皮膜成分中のスフィンゴミエリンの含有量が、1%以上、更に2%以上、更に3%以上であるのが好ましく、また、風味・ハンドリングの点から、50%以下、更に30%以下、更に25%以下、更に20%以下であるのが好ましい。また、脂肪球皮膜成分中のスフィンゴミエリンの含有量は、1〜50%、更に2〜30%、更に3〜25%、更に3〜20%が好ましい。
同様の点から、脂肪球皮膜成分の全リン脂質中のスフィンゴミエリン含有量が、3%以上、更に5%以上、更に10%以上、更に15%以上であるのが好ましく、また、50%以下、更に40%以下、更に35%以下、更に30%以下であるのが好ましい。また、脂肪球皮膜成分の全リン脂質中のスフィンゴミエリン含有量は、3〜50%、更に5〜40
%、更に10〜35%、更に15〜30%が好ましい。
なお、本明細書において、脂肪球皮膜成分中の脂質、リン脂質及びスフィンゴミエリンの含有量、並びに脂肪球皮膜成分の全リン脂質中のスフィンゴミエリン含有量は、脂肪球皮膜成分の乾燥物に対する質量割合とする。
In addition, the (A) fat globule membrane component preferably has a phospholipid content of 5% or more, further 8% or more, further 10% or more, and further 15% or more from the viewpoint of physiological effects. From the viewpoint of handling, it is preferably 100% or less, more preferably 85% or less, further 70% or less, and further preferably 60% or less. The content of phospholipid in the fat globule membrane component is preferably 5 to 100%, more preferably 8 to 90%, further 10 to 70%, and further preferably 15 to 60%.
The (A) fat globule membrane component preferably contains sphingomyelin as a phospholipid from the viewpoint of physiological effects, and the content of sphingomyelin in the fat globule membrane component is 1% or more, further 2% or more, Further, it is preferably 3% or more, and from the viewpoint of flavor and handling, it is preferably 50% or less, more preferably 30% or less, further 25% or less, and further preferably 20% or less. The content of sphingomyelin in the fat globule membrane component is preferably 1 to 50%, more preferably 2 to 30%, further 3 to 25%, and further preferably 3 to 20%.
From the same point, the sphingomyelin content in the total phospholipid of the fat globule membrane component is preferably 3% or more, more preferably 5% or more, further 10% or more, and further preferably 15% or more, and 50% or less. Further, it is preferably 40% or less, further 35% or less, and further preferably 30% or less. The sphingomyelin content in the total phospholipids of the fat globule membrane component is 3 to 50%, more preferably 5 to 40.
%, Further 10 to 35%, more preferably 15 to 30%.
In the present specification, the content of lipid, phospholipid and sphingomyelin in the fat globule membrane component, and the sphingomyelin content in the total phospholipid of the fat globule membrane component are the mass of the fat globule membrane component with respect to the dried product. A percentage.
上記の(A)脂肪球皮膜成分は、原料乳から遠心分離法や有機溶剤抽出法等の公知の方法により得ることができる。例えば、特開平3−47192号公報に記載の脂肪球皮膜成分の調製方法を用いることができる。また、特許第3103218号公報、特開2007−89535号公報に記載の方法等を用いることができる。さらに、透析、硫安分画、ゲルろ過、等電点沈殿、イオン交換クロマトグラフィー、溶媒分画等の手法により精製することにより純度を高めたものを用いてもよい。
なお、(A)脂肪球皮膜成分の形態は、特に限定されず、室温(15〜25℃)で液状、半固体状(ペースト等)、固体状(粉末、固形、顆粒等)等のいずれでもよく、これらを単独で又は2種以上組み合わせて用いてもよい。
Said (A) fat globule membrane | film | coat component can be obtained from well-known methods, such as a centrifugation method and an organic-solvent extraction method, from raw material milk. For example, the method for preparing a fat globule film component described in JP-A-3-47192 can be used. Also, the methods described in Japanese Patent No. 3103218 and Japanese Patent Application Laid-Open No. 2007-89535 can be used. Furthermore, you may use what improved purity by refine | purifying with methods, such as a dialysis, an ammonium sulfate fraction, gel filtration, isoelectric precipitation, ion-exchange chromatography, and a solvent fraction.
In addition, the form of the (A) fat globule membrane component is not particularly limited, and any of liquid, semi-solid (paste, etc.), solid (powder, solid, granule, etc.) at room temperature (15-25 ° C.) These may be used alone or in combination of two or more.
(A)脂肪球皮膜成分の原料乳としては、牛乳やヤギ乳等が挙げられる。なかでも、食経験が豊富であり、安価な点から、牛乳が好ましい。また、原料乳には、生乳、全粉乳や加工乳等の乳の他、乳製品も含まれ、乳製品としては、バターミルク、バターオイル、バターセーラム、ホエータンパク質濃縮物(WPC)等が挙げられる。
バターミルクは、牛乳等を遠心分離して得られるクリームからバター粒を製造する際に得られ、当該バターミルク中に脂肪球皮膜成分が多く含まれているので、脂肪球皮膜成分としてバターミルクをそのまま使用してもよい。同様に、バターオイルを製造する際に生じるバターセーラム中にも脂肪球皮膜成分が多く含まれているので、脂肪球皮膜成分としてバターセーラムをそのまま使用してもよい。
(A) Examples of the raw milk for the fat globule membrane component include milk and goat milk. Of these, milk is preferred because of its rich food experience and low cost. In addition, raw milk includes milk such as raw milk, whole milk powder and processed milk, as well as dairy products. Examples of dairy products include buttermilk, butter oil, buttersarum, whey protein concentrate (WPC) and the like. It is done.
Buttermilk is obtained when producing butter granules from cream obtained by centrifuging milk and the like. Since the buttermilk contains a lot of fat globule membrane components, buttermilk is used as a fat globule membrane component. It may be used as it is. Similarly, since the fat globule film component is contained in the butter serum produced when producing the butter oil, the butter serum may be used as it is as the fat globule film component.
(A)脂肪球皮膜成分は、市販品を用いることもできる。斯かる市販品としては、メグレジャパン(株)「BSCP」、雪印乳業(株)「ミルクセラミドMC−5」、(株)ニュージーランドミルクプロダクツ「Phospholipid Concentrate シリーズ(500,700)」等が挙げられる。 (A) A commercial item can also be used for a fat globule membrane component. Examples of such commercially available products include Megle Japan Co., Ltd. “BSCP”, Snow Brand Milk Products Co., Ltd. “Milk Ceramide MC-5”, New Zealand Milk Products “Phospholipid Concentrate Series (500, 700)”, and the like.
本発明の固形状組成物中、(A)脂肪球皮膜成分の配合量は20%以上であるが、生理効果を有効に発現する点、摂取形態として一度に少量の摂取で可能であるという点から、25%以上、更に30%以上、更に35%以上、更に40%以上が好ましく、また、摂食時の口内でのねとつき・付着が少ないという点で70%以下、更に60%以下、更に55%以下、更に50%以下が好ましい。また、固形状組成物中の(A)脂肪球皮膜成分の配合量は、20〜70%、更に20〜60%、更に25〜55%、更に30〜50%が好ましい。
なお、固形状組成物中の配合量は、固形状組成物原料の合計質量に対して配合(添加)される量である。
In the solid composition of the present invention, the blending amount of the (A) fat globule film component is 20% or more, but the point that the physiological effect is effectively expressed and that it is possible to ingest a small amount at once as an ingestion form. 25% or more, further 30% or more, further 35% or more, more preferably 40% or more, and 70% or less, and further 60% or less in terms of less stickiness and adhesion in the mouth when eating. Further, it is preferably 55% or less, more preferably 50% or less. Moreover, the compounding quantity of the (A) fat globule membrane | film | coat component in a solid composition is 20 to 70%, Furthermore, 20 to 60%, Furthermore, 25 to 55%, Furthermore, 30 to 50% is preferable.
In addition, the compounding quantity in a solid composition is the quantity mix | blended (added) with respect to the total mass of a solid composition raw material.
本発明の固形状組成物は、効果を有効に発現する点から、リン脂質を1%以上、更に2%以上、更に3%以上、更に4%以上含むことが好ましく、また、摂食時の口内でのねとつき・付着が少ないという点で60%以下、更に50%以下、更に40%以下、更に30%以下で含むことが好ましい。たとえば、リン脂質の含有量は、1〜60%、更に2〜50%、更に3〜40%、更に4〜30%が好ましい。 The solid composition of the present invention preferably contains 1% or more, further 2% or more, further 3% or more, and further 4% or more of phospholipid from the viewpoint of effectively expressing the effect. 60% or less, further 50% or less, further 40% or less, and further 30% or less is preferable in terms of less stickiness and adhesion in the mouth. For example, the phospholipid content is preferably 1 to 60%, more preferably 2 to 50%, further 3 to 40%, and more preferably 4 to 30%.
また、本発明の固形状組成物は、生理機能の点から、スフィンゴミエリンを0.5%以上、更に0.7%以上、更に1%以上含むことが好ましく、また、摂食時の口内でのねとつき・付着が少ないという点で3.5%以下、更に3%以下含むことが好ましい。例えば、スフィンゴミエリンの含有量は、0.5〜3.5%、更に0.7〜3.5%、更に1〜3%が好ましい。
固形状組成物中のリン脂質及びスフィンゴミエリンは、(A)脂肪球皮膜成分以外の配合成分に由来するもの、別途配合された化学的に合成されたもの等でもあってもよいが、脂肪球皮膜成分に由来するものであるのが好ましい。
脂肪球皮膜成分中又は固形状組成物中の脂質及びリン脂質の含有量は、酸分解法、比色法又は薄層クロマトグラフ法により測定することができる。
In addition, the solid composition of the present invention preferably contains 0.5% or more, further 0.7% or more, and further 1% or more of sphingomyelin from the viewpoint of physiological function. It is preferably 3.5% or less, and more preferably 3% or less in terms of less stickiness and adhesion. For example, the sphingomyelin content is preferably 0.5 to 3.5%, more preferably 0.7 to 3.5%, and further preferably 1 to 3%.
The phospholipid and sphingomyelin in the solid composition may be derived from a blending component other than the (A) fat globule film component, or may be a chemically synthesized compound blended separately. It is preferably derived from a film component.
The lipid and phospholipid contents in the fat globule membrane component or in the solid composition can be measured by an acid decomposition method, a colorimetric method, or a thin layer chromatographic method.
本発明の固形状組成物には、(B)乳糖を配合する。乳糖は、無水物、水和物のいずれでもよい。
本発明の固形状組成物中、(B)乳糖の配合量は5%以上であるが、効果を有効に発現する点から、10%以上であるのが好ましく、また、物性の点で、60%以下、更に35%以下が好ましい。また、固形状組成物中の(B)乳糖の配合量は、5〜60%、更に10〜50%、更に10〜35%が好ましい。
(B) Lactose is mix | blended with the solid composition of this invention. Lactose may be either an anhydride or a hydrate.
In the solid composition of the present invention, the blending amount of (B) lactose is 5% or more, but is preferably 10% or more from the viewpoint of effectively producing the effect, and 60% from the viewpoint of physical properties. % Or less, more preferably 35% or less. Further, the blending amount of (B) lactose in the solid composition is preferably 5 to 60%, more preferably 10 to 50%, and further preferably 10 to 35%.
また、本発明の固形状組成物には、(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類を配合する。
乳糖以外の二糖類としては、例えば、ショ糖、麦芽糖、トレハロース等が挙げられる。また、単糖類としては、例えば、ブドウ糖、果糖、ガラクトース等が挙げられる。これらは単独で又は2種以上を組み合わせて用いることができる。これらの糖類も無水物又は水和物であってもよい。
なかでも、風味の点から、ショ糖、ブドウ糖、果糖が好ましく、ショ糖がより好ましい。ショ糖は、清浄精製した白色の砂糖である白糖が好ましい。白糖としては、例えば、上白糖、グラニュー糖、粉糖、白双糖、氷砂糖、角砂糖等が挙げられ、グラニュー糖、粉糖が好ましく、粉糖がより好ましい。
The solid composition of the present invention contains (C) at least one saccharide selected from disaccharides other than lactose and monosaccharides.
Examples of disaccharides other than lactose include sucrose, maltose, trehalose and the like. Moreover, as monosaccharide, glucose, fructose, galactose etc. are mentioned, for example. These can be used alone or in combination of two or more. These saccharides may also be anhydrides or hydrates.
Of these, sucrose, glucose, and fructose are preferable from the viewpoint of flavor, and sucrose is more preferable. The sucrose is preferably white sugar, which is a clean and purified white sugar. Examples of white sugar include fine white sugar, granulated sugar, powdered sugar, white disaccharide, icing sugar, and sugar sugar. Granulated sugar and powdered sugar are preferable, and powdered sugar is more preferable.
本発明の固形状組成物中、(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類の配合量は、効果を有効に発現する点から、10%以上であるのが好ましく、更に20%以上が好ましい。また、物性の点で60%以下、更に50%以下が好ましい。また、固形状組成物中の(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類の配合量は、10〜60%、更に20〜50%が好ましい。
なお、糖類の定量法としては、フェノール硫酸法、Somogyi−Nelson法を用いることができる。
In the solid composition of the present invention, (C) the blending amount of at least one saccharide selected from disaccharides other than lactose and monosaccharides is 10% or more from the viewpoint of effectively expressing the effect. Is preferable, and further 20% or more is preferable. In terms of physical properties, it is preferably 60% or less, and more preferably 50% or less. The blending amount of at least one saccharide selected from (C) disaccharides other than lactose and monosaccharides in the solid composition is preferably 10 to 60%, more preferably 20 to 50%.
In addition, as a quantification method of saccharides, a phenol sulfuric acid method and a Somogyi-Nelson method can be used.
本発明の固形状組成物において、固形状組成物中の(A)脂肪球皮膜成分の配合量に対する、固形状組成物中の成分(B)と成分(C)の合計配合量の比(配合質量比)[{(B)+(C)}/(A)]は0.5〜3.5であるが、風味の点・物性の点から、0.75以上、更に0.8以上が好ましく、また、乳風味の点から2以下、更に1.5以下が好ましい。 In the solid composition of the present invention, the ratio of the total blending amount of the component (B) and the component (C) in the solid composition to the blending amount of the (A) fat globule film component in the solid composition (blending (Mass ratio) [{(B) + (C)} / (A)] is 0.5 to 3.5, but from the point of flavor and physical properties, it is 0.75 or more, and further 0.8 or more. It is preferably 2 or less, more preferably 1.5 or less from the viewpoint of milk flavor.
また、本発明の固形状組成物において、固形状組成物中の成分(B)と成分(C)の合計配合量に対する、固形状組成物中の成分(B)の配合量の比(配合質量比)[(B)/{(B)+(C)}]は0.08〜0.72であるが、風味の点から、0.09以上、更に0.3以上が好ましく、また、錠剤物性の点から0.7以下が好ましい。 Moreover, in the solid composition of the present invention, the ratio of the blending amount of the component (B) in the solid composition to the total blending amount of the component (B) and the component (C) in the solid composition (blending mass) Ratio) [(B) / {(B) + (C)}] is 0.08 to 0.72, preferably 0.09 or more, more preferably 0.3 or more from the viewpoint of flavor, and tablets 0.7 or less is preferable from the viewpoint of physical properties.
本発明の固形状組成物には、上記成分の他に本発明の効果を損なわない範囲において、ミネラル(例えば、鉄、亜鉛、クロム、セレン、マンガン、モリブデン、銅、ヨウ素、リン、カリウム、ナトリウム)、ビタミン(例えば、ビタミンA、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、葉酸及びそれらの塩、又はそれらのエステル)、甘味料(例えば、糖アルコール、オリゴ糖、合成甘味料)、酸味料(例えば、クエン酸、リンゴ酸、酒石酸、乳酸、コハク酸、アジピン酸、グルコノデルタラクトン、グルコン酸、酢酸、フマル酸)、香料、着色料、保存料等が適宜配合されていてもよい。 In the solid composition of the present invention, in addition to the above components, minerals (for example, iron, zinc, chromium, selenium, manganese, molybdenum, copper, iodine, phosphorus, potassium, sodium) ), Vitamins (eg, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, folic acid and their salts, or esters thereof), sweeteners (eg, sugar alcohols, oligosaccharides, synthetic sweeteners) ), Acidulants (for example, citric acid, malic acid, tartaric acid, lactic acid, succinic acid, adipic acid, glucono delta lactone, gluconic acid, acetic acid, fumaric acid), flavors, coloring agents, preservatives and the like are appropriately blended. May be.
本発明の固形状組成物は、室温(15〜25℃)で粉末、固形、顆粒等の固形状態のものを意味する。製剤(剤型)としては、例えば、カプセル剤、顆粒剤、散剤、錠剤、丸剤、トローチ剤等が挙げられる。なかでも、摂取が簡便な点から、咀嚼摂取する形態が好ましく、更にチュアブル錠、トローチ剤が好ましく、チュアブル錠がより好ましい。また、錠剤とする場合には、割線を入れた分割錠とすることもできる。
このような剤型の固形状組成物を製造する際には、必要に応じて許容される担体を配合することができる。例えば、賦形剤(例えば、デンプン類、結晶セルロース、軽質無水ケイ酸、リン酸水素カルシウム等)、結合剤(例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ゼラチン、アルファー化デンプン、ポリビニルピロリドン、ポリビニルアルコール、プルラン、メチルセルロース、硬化油等)、崩壊剤(例えば、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、クロスポピドン、トウモロコシデンプン、低置換度ヒドロキシプロピルセルロース等)、滑沢剤(例えば、ステアリン酸カルシウム、ステアリン酸マグネシウム、ショ糖脂肪酸エステル、フマル酸ステアリルナトリウム、タルク、二酸化ケイ素等)、嬌味剤(例えば、ステビア等)、増量剤、界面活性剤、分散剤、緩衝剤、保存剤、希釈剤等の担体が挙げられる。
The solid composition of the present invention means a solid composition such as powder, solid or granule at room temperature (15 to 25 ° C.). Examples of the preparation (dosage form) include capsules, granules, powders, tablets, pills, troches and the like. Among these, from the point of easy intake, the form of chewing and ingesting is preferable, chewable tablets and lozenges are more preferable, and chewable tablets are more preferable. Moreover, when it is set as a tablet, it can also be set as the split tablet which put the score line.
When producing such a solid composition in dosage form, an acceptable carrier can be blended as necessary. For example, excipients (for example, starches, crystalline cellulose, light anhydrous silicic acid, calcium hydrogen phosphate, etc.), binders (for example, hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol , Pullulan, methylcellulose, hydrogenated oil, etc.), disintegrating agents (eg, carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, low substituted hydroxypropylcellulose, etc.), lubricants (eg, calcium stearate, Magnesium stearate, sucrose fatty acid ester, sodium stearyl fumarate, talc, silicon dioxide, etc.), flavoring agent (eg, stevia), bulking agent, surfactant, dispersant, buffering agent, Presence agents, carriers such as diluents.
固形状組成物の形状としては、円形錠又は楕円形、長円形、四角形等の面形を有する各種異形錠であってもよい。円形錠の場合、服用性の点から、直径5〜15mmが好ましい。 The shape of the solid composition may be a round tablet or various irregular tablets having a surface shape such as an oval, an oval, or a quadrangle. In the case of a circular tablet, a diameter of 5 to 15 mm is preferable from the viewpoint of ingestibility.
本発明の固形状組成物が錠剤の場合、1錠当たりの重量は0.1〜2g、更に0.3〜1gとするのが、簡便性及び有効性の点で好ましい。
また、錠剤硬度は、運搬、全自動錠剤分包機や押出式薬剤包装機(PTP)から押出す際の負荷、保存等に耐え得る硬度であることが好ましく、10N〜140Nが好ましく、12N〜90Nがより好ましい。
When the solid composition of the present invention is a tablet, the weight per tablet is preferably 0.1 to 2 g, more preferably 0.3 to 1 g from the viewpoint of simplicity and effectiveness.
Moreover, it is preferable that tablet hardness is a hardness which can endure the load at the time of conveyance, the extrusion at the time of a fully automatic tablet packaging machine or an extrusion-type medicine packaging machine (PTP), a preservation | save, etc., 10N-140N are preferable, 12N-90N Is more preferable.
本発明の固形状組成物は、特に制限はなく常法に従い製造される。例えば、(A)脂肪球皮膜成分、(B)乳糖、(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類、及び必要に応じて添加される添加剤の混合物を調製後、圧縮成形することによって製造することができる。
錠剤は、前記混合物を直接圧縮して成形(直接粉末圧縮法)しても、乾式造粒法、湿式造粒法等を用いて造粒してから圧縮して成形(顆粒圧縮法)しても良い。なかでも、工程の簡便性の点から、直接粉末圧縮法を用いて錠剤とするのが好ましい。
直接圧縮して成形して錠剤を製造する場合、打錠成形機としてはロータリー式打錠機や単発式打錠機等通常使用されるものを用いることができる。
また、造粒法より造粒してから錠剤とする場合、円筒造粒機、球形整粒機、ペレッター等を使用する押し出し造粒法;スピードミル、パワーミル等を使用する破砕造粒法;転動造粒法、攪拌造粒法、流動層造粒法等により造粒物を製造し、乾燥・整粒した後、得られた造粒物を前記打錠成形機で圧縮して錠剤を形成できる。
The solid composition of the present invention is produced according to a conventional method without any particular limitation. For example, a mixture of (A) fat globule membrane component, (B) lactose, (C) at least one saccharide selected from disaccharides other than lactose, and monosaccharides, and an additive added as necessary After preparation, it can be produced by compression molding.
Tablets can be molded by directly compressing the mixture (direct powder compression method), or granulated using dry granulation method, wet granulation method, etc. and then compressed (granule compression method) Also good. Especially, it is preferable to use a direct powder compression method to make a tablet from the point of simplicity of the process.
When a tablet is produced by direct compression and molding, a conventional tableting machine such as a rotary tableting machine or a single-shot tableting machine can be used.
In addition, when a tablet is formed after granulation by a granulation method, an extrusion granulation method using a cylindrical granulator, a spherical granulator, a pelleter, etc .; a crushing granulation method using a speed mill, a power mill, etc .; A granulated product is produced by dynamic granulation method, stirring granulation method, fluidized bed granulation method, etc., dried and sized, and then the obtained granulated product is compressed by the tableting machine to form tablets. it can.
打錠時の圧縮成形圧は、成形物の硬度維持、崩壊性等の点から、10〜30MPa程度が好ましい。 The compression molding pressure at the time of tableting is preferably about 10 to 30 MPa from the viewpoint of maintaining the hardness of the molded product, disintegrating property, and the like.
[分析方法]
(1)タンパク質の分析
タンパク質量はケルダール法を用いて、窒素・タンパク質換算係数6.38として求めた。
[Analysis method]
(1) Protein analysis The amount of protein was determined as a nitrogen / protein conversion factor 6.38 using the Kjeldahl method.
(2)脂質の分析
脂質量は酸分解法で求めた。試料を1g量りとり、塩酸を加え分解した後、ジエチルエーテル及び石油エーテルを加え、攪拌混和した。エーテル混合液層を取り出し、水洗した。溶媒を留去させ、乾燥させた後、重量を秤量することで脂質量を求めた。
(2) Analysis of lipid The amount of lipid was determined by an acid decomposition method. 1 g of a sample was weighed and decomposed with hydrochloric acid, and then diethyl ether and petroleum ether were added and mixed with stirring. The ether mixture layer was taken out and washed with water. After the solvent was distilled off and dried, the amount of lipid was determined by weighing the weight.
(3)炭水化物の分析
炭水化物量は試料の質量から試料中のタンパク質量、脂質質量、灰分量、及び水分量を除くことにより求めた。なお、灰分量は直接灰化法(550℃で試料を灰化させ重量測定)、水分量は常圧加熱乾燥法(105℃4時間乾燥させ重量測定)により求めた。
(3) Carbohydrate analysis The amount of carbohydrate was determined by excluding the amount of protein, the mass of lipid, the amount of ash, and the amount of water in the sample from the mass of the sample. The amount of ash was determined by the direct ashing method (the sample was ashed at 550 ° C. and weighed), and the amount of water was determined by the atmospheric pressure heating drying method (105 ° C. for 4 hours and weighed).
(4)リン脂質の分析
試料1gを量りとり、クロロホルム及びメタノールの2:1(V/V)混液150mL、100mL、及び20mL中でホモジナイズ後、0.88%(W/V)塩化カリウム水溶液93mLを添加し、一晩室温で放置した。脱水ろ過、溶媒留去後、クロロホルムを添加し総量を50mLとした。そのうち2mLを分取し、溶媒留去後、550℃16時間加熱処理により灰化した。灰分を6M塩酸水溶液5mLに溶解後、蒸留水を添加し、総量を50mLとした。3mLを分取し、モリブデンブルー発色試薬5mL、5%(W/V)アスコルビン酸水溶液1mL及び蒸留水を添加し総量を50mLとし、710nmの吸光度を測定した。リン酸2水素カリウムを用いた検量線からリン量を求め、リン量に25.4をかけた値をリン脂質量とした。
(4) Analysis of phospholipid A 1 g sample was weighed and homogenized in 150 mL, 100 mL, and 20 mL of a 2: 1 (V / V) mixture of chloroform and methanol, and then 93 mL of 0.88% (W / V) aqueous potassium chloride solution. Was added and left at room temperature overnight. After dehydration filtration and solvent distillation, chloroform was added to make the total volume 50 mL. Of this, 2 mL was collected and the solvent was distilled off, followed by ashing by heat treatment at 550 ° C. for 16 hours. After the ash was dissolved in 5 mL of 6M hydrochloric acid aqueous solution, distilled water was added to make the total amount 50 mL. 3 mL was fractionated, 5 mL of molybdenum blue coloring reagent, 1 mL of 5% (W / V) ascorbic acid aqueous solution and distilled water were added to make the total amount 50 mL, and the absorbance at 710 nm was measured. The amount of phosphorus was determined from a calibration curve using potassium dihydrogen phosphate, and the value obtained by multiplying the amount of phosphorus by 25.4 was taken as the amount of phospholipid.
(5)スフィンゴミエリンの分析
試料1gを量りとり、クロロホルム及びメタノールの2:1(V/V)混液150mL、100mL、及び20mL中でホモジナイズ後、0.88%(W/V)塩化カリウム水溶液93mLを添加し、一晩室温で放置した。脱水ろ過、溶媒留去後、クロロホルムを添加し総量を50mLとした。そのうち10mLを分取し、シリカカートリッジカラムに添加した。カラムをクロロホルム20mLで洗浄後、メタノール30mLでリン脂質を溶出し、溶媒留去後クロロホルム1.88mLに溶解した。シリカゲル薄層プレートに20μLを負荷し、1次元展開溶媒としてテトラヒドロフラン:アセトン:メタノール:水=50:20:40:8(V/V)、2次元展開溶媒としてクロロホルム:アセトン:メタノール:酢酸:水=50:20:10:15:5(V/V)を用いて2次元展開を行った。展開後の薄層プレートにディトマー試薬を噴霧し、スフィンゴミエリンのスポットをかきとり、3%(V/V)硝酸含有過塩素酸溶液2mL添加後、170℃3時間の加熱処理を行った。蒸留水5mL添加後モリブデンブルー発色試薬5mL、5%(W/V)アスコルビン酸水溶液1mL及び蒸留水を添加し総量を50mLとし、710nmの吸光度を測定した。リン酸2水素カリウムを用いた検量線からリン量を求め、リン量に25.4をかけた値をスフィンゴミエリン量とした。
(5) Analysis of sphingomyelin 1 g of a sample was weighed and homogenized in 150 mL, 100 mL, and 20 mL of a 2: 1 (V / V) mixture of chloroform and methanol, and then 93 mL of 0.88% (W / V) aqueous potassium chloride solution. Was added and left at room temperature overnight. After dehydration filtration and solvent distillation, chloroform was added to make the total volume 50 mL. 10 mL of this was collected and added to a silica cartridge column. The column was washed with 20 mL of chloroform, phospholipid was eluted with 30 mL of methanol, the solvent was distilled off, and the residue was dissolved in 1.88 mL of chloroform. A silica gel thin layer plate was loaded with 20 μL, and tetrahydrofuran: acetone: methanol: water = 50: 20: 40: 8 (V / V) as a one-dimensional developing solvent chloroform: acetone: methanol: acetic acid: water as a two-dimensional developing solvent. = Two-dimensional development was performed using 50: 20: 10: 15: 5 (V / V). The developed thin-layer plate was sprayed with a ditomer reagent, the sphingomyelin spot was scraped off, and 2 mL of a 3% (V / V) nitric acid-containing perchloric acid solution was added, followed by heat treatment at 170 ° C. for 3 hours. After adding 5 mL of distilled water, 5 mL of molybdenum blue coloring reagent, 1 mL of 5% (W / V) ascorbic acid aqueous solution and distilled water were added to make the total amount 50 mL, and the absorbance at 710 nm was measured. The amount of phosphorus was determined from a calibration curve using potassium dihydrogen phosphate, and the value obtained by multiplying the amount of phosphorus by 25.4 was taken as the amount of sphingomyelin.
[原料]
脂肪球皮膜成分1:BSCP、メグレジャパン(株)(水分3.0%)
脂肪球皮膜成分2:ミルクセラミドMC−5、雪印乳業(株)(水分1.6%)
乳糖:ラクトース、レプリノフーズ
ショ糖:フロストシュガーFS−2、日新製糖(株)
ブドウ糖:粉末ブドウ糖、サンエイ糖化(株)
果糖:果糖、三育フーズ(株)
コーンスターチ:日食コーンスターチ、日本食品化工 (株)
アスパルテーム:PAL SWEET DIET、味の素(株)
[material]
Fat globule membrane component 1: BSCP, Megre Japan (water content 3.0%)
Fat globule membrane component 2: Milk Ceramide MC-5, Snow Brand Milk Products Co., Ltd. (moisture 1.6%)
Lactose: Lactose, Replino sucrose: Frost sugar FS-2, Nissin Sugar Co., Ltd.
Glucose: Powdered glucose, Sanei Saccharification Co., Ltd.
Fructose: Fructose, Saniku Foods Co., Ltd.
Cornstarch: Solar eclipse cornstarch, Nippon Shokuhin Kako Co., Ltd.
Aspartame: PAL SWEET DIET, Ajinomoto Co., Inc.
脂肪球皮膜成分1の組成は、乾燥物換算で、炭水化物:10.7%、脂質:23.8%、タンパク質:50.9%であった。また、脂肪球皮膜成分1中、リン脂質含有量は16.6%であった。スフィンゴミエリン含有量は3.62%であった。
脂肪球皮膜成分2の組成は、乾燥物換算で、炭水化物:26.1%、脂質:43.3%、タンパク質:21.2%であった。また、脂肪球皮膜成分2中、リン脂質含有量は33.3%であった。スフィンゴミエリン含有量は8.03%であった。
The composition of fat globule membrane component 1 was carbohydrate: 10.7%, lipid: 23.8%, protein: 50.9% in terms of dry matter. In fat globule membrane component 1, the phospholipid content was 16.6%. The sphingomyelin content was 3.62%.
The composition of fat globule membrane component 2 was 26.1% carbohydrates, 43.3% lipids, and 21.2% proteins in terms of dry matter. In fat globule membrane component 2, the phospholipid content was 33.3%. The sphingomyelin content was 8.03%.
〔チュアブル錠の調製〕
実施例1〜実施例16及び比較例1〜比較例9
粒径の大きい原料は粉砕し、50メッシュに通したのち、表1に記載の配合組成で各原料成分を混合した。次に単発式打錠機(RIKEN製)を用いて、穴径9.5mmのリング状杵で、錠剤重量500mgで打錠し、チュアブル錠を得た。
[Preparation of chewable tablets]
Examples 1 to 16 and Comparative Examples 1 to 9
The raw material having a large particle size was pulverized and passed through 50 mesh, and then each raw material component was mixed with the composition shown in Table 1. Next, using a single-type tableting machine (manufactured by RIKEN), the tablet was tableted at a tablet weight of 500 mg with a ring-shaped punch with a hole diameter of 9.5 mm to obtain a chewable tablet.
上記で得た本発明品と比較品について官能評価を行なった。評価は、サンプルを食べた時の風味と脂肪球皮膜成分由来の乳風味、及び口内付着性について、下記に示す判断基準に従って専門パネル2名で先ず全てのサンプルについて評価を行い、評価が最も高かった例を「5」、評価が最も低かった例を「1」とした。次いで、その他のサンプルについて「1」〜「5」の間の5段階尺度による相対的位置づけを行った。2名の平均値をもって評点(0.5刻みで四捨五入)とした。
また、サンプルの硬度を測定した。結果を表1に示す。
Sensory evaluation was performed on the product of the present invention and the comparative product obtained above. Evaluation was performed on all samples first by two specialist panels according to the criteria shown below for the flavor when eating the sample, the milk flavor derived from the fat globule membrane component, and the oral adherence. The example was “5”, and the example with the lowest evaluation was “1”. Next, relative positioning was performed on the other samples on a 5-step scale between “1” and “5”. The average value of the two people was used as the score (rounded off to the nearest 0.5).
Moreover, the hardness of the sample was measured. The results are shown in Table 1.
〔摂食時の風味の広がり〕
実施例2を「5」、比較例7を「1」とし評価した。具体的には以下のような項目で評価した。
5:風味が口の中に強く広がり、非常に良好
4:風味が口の中に広がり、良好
3:風味が口の中にやや広がり、やや良好
2:風味が口の中にやや広がらず、やや良くない
1:風味が口の中に広がらず、良くない
[Spreading flavor during eating]
Example 2 was evaluated as “5” and Comparative Example 7 as “1”. Specifically, the following items were evaluated.
5: Flavor spreads strongly in the mouth, very good 4: Flavor spreads in the mouth, Good 3: Flavor spreads slightly in the mouth, Slightly good 2: Flavor does not spread slightly in the mouth, Slightly bad 1: The flavor does not spread in the mouth and is not good
〔脂肪球皮膜成分由来の乳風味の強さ〕
実施例6を「5」、比較例9を「1」とし評価した。具体的には以下のような項目で評価した。
5:良好な乳風味を非常に強く感じる
4:良好な乳風味を強く感じる
3:良好な乳風味を感じる
2:良好な乳風味を殆ど感じない
1:良好な乳風味を感じない
[Strength of milk flavor derived from fat globule membrane components]
Evaluation was made with Example 6 as “5” and Comparative Example 9 as “1”. Specifically, the following items were evaluated.
5: Feels a good milk flavor very strongly 4: Feels a good milk flavor strong 3: Feels a good milk flavor 2: Does not feel a good milk flavor 1: Does not feel a good milk flavor
〔口内付着性〕
実施例2を「5」、比較例2を「1」とし評価した。具体的には以下のような項目で評価した。
5:歯や舌への付着性が非常に弱い
4:歯や舌への付着性が弱い
3:歯や舌への付着性がわずかに強い
2:歯や舌への付着性が強い
1:歯や舌への付着性が非常に強い
(Oral adhesion)
Example 2 was evaluated as “5” and Comparative Example 2 as “1”. Specifically, the following items were evaluated.
5: Adhesion to teeth and tongue is very weak 4: Adhesion to teeth and tongue is weak 3: Adhesion to teeth and tongue is slightly strong 2: Adhesion to teeth and tongue is strong 1: Very strong adhesion to teeth and tongue
〔硬度〕
製造直後のサンプルについて、FUJIWARA HARDNESS TESTER(藤原製作所製)を用いて直径方向の硬度を測定した。試験は2錠で行い、その平均値をサンプル硬度とした。
〔hardness〕
About the sample immediately after manufacture, the hardness of the diameter direction was measured using FUJIWARA HARDNESS TESTER (made by Fujiwara Seisakusho). The test was performed with 2 tablets, and the average value was taken as the sample hardness.
表1から明らかなように、乳糖と乳糖以外の糖類を所定の範囲で配合した実施例1〜16は脂肪球皮膜成分に由来する良好な乳風味が強く感じられ、摂食時の風味が良好で、口内でのべたつき感もなかった。また、成形可能であった。
これに対し、乳糖と乳糖以外の糖類を所定の範囲で配合しない比較例1〜9は脂肪球皮膜成分の乳風味が弱く、比較例1、2、5〜7は口内でのべたつき・ねとつきが感じられた。また、比較例2、6〜8は打錠時に崩れやすく、もろかった。
As is clear from Table 1, Examples 1 to 16 in which lactose and saccharides other than lactose were blended within a predetermined range strongly felt a good milk flavor derived from the fat globule membrane component, and the flavor during eating was good. And there was no stickiness in the mouth. Moreover, it was moldable.
On the other hand, Comparative Examples 1 to 9 in which lactose and saccharides other than lactose are not blended in a predetermined range are weak in the milk flavor of the fat globule membrane component, and Comparative Examples 1, 2, and 5 to 7 are sticky / neat in the mouth. There was a feeling. Further, Comparative Examples 2 and 6 to 8 were fragile and easily broken during tableting.
Claims (7)
(A)脂肪球皮膜成分 20質量%以上、
(B)乳糖 5質量%以上、
(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類
を配合してなり、成分(A)の配合量に対する成分(B)と成分(C)の合計配合量の比(配合質量比)[{(B)+(C)}/(A)]が0.5〜3.5、且つ成分(B)と成分(C)の合計配合量に対する成分(B)の配合量の比(配合質量比)[(B)/{(B)+(C)}]が0.08〜0.72である固形状組成物。 The following components (A), (B) and (C):
(A) Fat globule film component 20% by mass or more,
(B) Lactose 5% by mass or more,
(C) At least one saccharide selected from disaccharides other than lactose and monosaccharides is blended, and the ratio of the total blending amount of component (B) and component (C) to the blending amount of component (A) (Blending mass ratio) [{(B) + (C)} / (A)] is 0.5 to 3.5, and blending of component (B) with respect to the total blending amount of component (B) and component (C) Solid composition whose ratio (blending mass ratio) [(B) / {(B) + (C)}] of the amount is 0.08 to 0.72.
(A)脂肪球皮膜成分、
(B)乳糖、
(C)乳糖以外の二糖類、及び単糖類から選択される少なくとも1種の糖類
を配合する工程を含む固形状組成物の製造方法であって、
成分(A)の配合量が全配合原料の合計質量に対して20質量%以上であり、
成分(B)の配合量が全配合原料の合計質量に対して5質量%以上であり、
成分(A)の配合量に対する成分(B)と成分(C)の合計配合量の比(配合質量比)[{(B)+(C)}/(A)]が0.5〜3.5であり、且つ
成分(B)と成分(C)の合計配合量に対する成分(B)の配合量の比(配合質量比)[(B)/{(B)+(C)}]が0.08〜0.72である、製造方法。 The following components (A), (B) and (C):
(A) Fat globule membrane component,
(B) Lactose,
(C) A method for producing a solid composition comprising a step of blending at least one saccharide selected from disaccharides other than lactose and monosaccharides,
The blending amount of component (A) is 20% by mass or more based on the total mass of all blended raw materials,
The blending amount of the component (B) is 5% by mass or more based on the total mass of all the blended raw materials,
The ratio of the total blending amount of component (B) and component (C) to the blending amount of component (A) (blending mass ratio) [{(B) + (C)} / (A)] is 0.5-3. 5 and the ratio of the blending amount of the component (B) to the total blending amount of the component (B) and the component (C) (blending mass ratio) [(B) / {(B) + (C)}] is 0. Manufacturing method which is 0.08 to 0.72.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015128641A JP6608193B2 (en) | 2014-06-27 | 2015-06-26 | Solid composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014132342 | 2014-06-27 | ||
JP2014132342 | 2014-06-27 | ||
JP2015128641A JP6608193B2 (en) | 2014-06-27 | 2015-06-26 | Solid composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016026491A true JP2016026491A (en) | 2016-02-18 |
JP6608193B2 JP6608193B2 (en) | 2019-11-20 |
Family
ID=55352183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015128641A Active JP6608193B2 (en) | 2014-06-27 | 2015-06-26 | Solid composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6608193B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9956246B2 (en) | 2014-06-27 | 2018-05-01 | Kao Corporation | Solid ingestible composition comprising a fat globule membrane component and water-soluble dietary fiber |
JP2020529200A (en) * | 2017-07-26 | 2020-10-08 | アボット ラボラトリーズ | Nutritional tablets and their manufacturing methods |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0530942A (en) * | 1991-07-25 | 1993-02-09 | Riyoushiyoku Kenkyukai | Drink and food and medicine having controlling effect on polymer permeability through intestinal tract |
JP2007320901A (en) * | 2006-05-31 | 2007-12-13 | Snow Brand Milk Prod Co Ltd | Agent for inhibiting visceral fat accumulation and agent for promoting increase in and/or inhibiting decrease in blood adiponectin concentration |
JP2008105971A (en) * | 2006-10-24 | 2008-05-08 | Nof Corp | Method for producing powder for tableting |
JP2010059155A (en) * | 2008-08-07 | 2010-03-18 | Kao Corp | Agent for improving exercise function |
JP2011157329A (en) * | 2010-02-03 | 2011-08-18 | Kao Corp | Mitochondria function-improving agent |
JP2011217645A (en) * | 2010-04-07 | 2011-11-04 | Adeka Corp | Concentrated milk-like composition |
JP2012510483A (en) * | 2008-12-03 | 2012-05-10 | アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bendamustine solid dosage form |
JP2013531059A (en) * | 2010-07-22 | 2013-08-01 | ルピン・リミテッド | Multi-unit tablet composition |
JP2013537900A (en) * | 2010-09-22 | 2013-10-07 | アルファ ワッセルマン ソシエタ ペル アチオニ | Pharmaceutical formulation comprising rifaximin, method for obtaining it and method for treating bowel disease |
JP2014047195A (en) * | 2012-09-03 | 2014-03-17 | Kao Corp | Cell membrane enhancer |
JP2014129285A (en) * | 2012-12-28 | 2014-07-10 | Kao Corp | Solid composition |
JP2015104345A (en) * | 2013-11-29 | 2015-06-08 | 株式会社Adeka | Water-in-oil type emulsified fat composition having plasticity |
JP2015113322A (en) * | 2013-12-13 | 2015-06-22 | 花王株式会社 | Agility improvement agent |
-
2015
- 2015-06-26 JP JP2015128641A patent/JP6608193B2/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0530942A (en) * | 1991-07-25 | 1993-02-09 | Riyoushiyoku Kenkyukai | Drink and food and medicine having controlling effect on polymer permeability through intestinal tract |
JP2007320901A (en) * | 2006-05-31 | 2007-12-13 | Snow Brand Milk Prod Co Ltd | Agent for inhibiting visceral fat accumulation and agent for promoting increase in and/or inhibiting decrease in blood adiponectin concentration |
JP2008105971A (en) * | 2006-10-24 | 2008-05-08 | Nof Corp | Method for producing powder for tableting |
JP2010059155A (en) * | 2008-08-07 | 2010-03-18 | Kao Corp | Agent for improving exercise function |
JP2012510483A (en) * | 2008-12-03 | 2012-05-10 | アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bendamustine solid dosage form |
JP2011157329A (en) * | 2010-02-03 | 2011-08-18 | Kao Corp | Mitochondria function-improving agent |
JP2011217645A (en) * | 2010-04-07 | 2011-11-04 | Adeka Corp | Concentrated milk-like composition |
JP2013531059A (en) * | 2010-07-22 | 2013-08-01 | ルピン・リミテッド | Multi-unit tablet composition |
JP2013537900A (en) * | 2010-09-22 | 2013-10-07 | アルファ ワッセルマン ソシエタ ペル アチオニ | Pharmaceutical formulation comprising rifaximin, method for obtaining it and method for treating bowel disease |
JP2014047195A (en) * | 2012-09-03 | 2014-03-17 | Kao Corp | Cell membrane enhancer |
JP2014129285A (en) * | 2012-12-28 | 2014-07-10 | Kao Corp | Solid composition |
JP2015104345A (en) * | 2013-11-29 | 2015-06-08 | 株式会社Adeka | Water-in-oil type emulsified fat composition having plasticity |
JP2015113322A (en) * | 2013-12-13 | 2015-06-22 | 花王株式会社 | Agility improvement agent |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9956246B2 (en) | 2014-06-27 | 2018-05-01 | Kao Corporation | Solid ingestible composition comprising a fat globule membrane component and water-soluble dietary fiber |
JP2020529200A (en) * | 2017-07-26 | 2020-10-08 | アボット ラボラトリーズ | Nutritional tablets and their manufacturing methods |
Also Published As
Publication number | Publication date |
---|---|
JP6608193B2 (en) | 2019-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6014493B2 (en) | Solid composition | |
JP5816760B1 (en) | Solid composition | |
JP6474256B2 (en) | Solid composition | |
JP6608193B2 (en) | Solid composition | |
JP6836368B2 (en) | Solid composition | |
JP6987613B2 (en) | Solid composition | |
JP6525586B2 (en) | Solid composition | |
JP6560959B2 (en) | Compression molding | |
JP5816761B1 (en) | Solid composition | |
JP6662608B2 (en) | Method for producing granulated material containing milk fat globule film component | |
JP6474255B2 (en) | Solid composition | |
JP6774675B2 (en) | Solid composition | |
JP5816762B1 (en) | Solid composition | |
JP6364347B2 (en) | Solid composition | |
JP7129537B2 (en) | solid composition | |
JP6669576B2 (en) | Solid composition | |
JP6446265B2 (en) | Solid composition | |
JP2017176133A (en) | Gummy candy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180319 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190613 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191023 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 6608193 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |